# 1/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)

> **NIH NIH UH3** · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2021 · $2,887,088


## Key facts

- **NIH application ID:** 10165800
- **Project number:** 5UH3HL143192-03
- **Recipient organization:** UNIVERSITY OF PITTSBURGH AT PITTSBURGH
- **Principal Investigator:** Mark T Gladwin
- **Activity code:** UH3 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $2,887,088
- **Award type:** 5
- **Project period:** 2019-05-15 → 2026-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10165800

## Citation

> US National Institutes of Health, RePORTER application 10165800, 1/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial) (5UH3HL143192-03). Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/grant/nih/10165800. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*